Medicenna Therapeutics Corp. (MDNA): Price and Financial Metrics
GET POWR RATINGS... FREE!
MDNA Stock Price Chart Interactive Chart >
MDNA Price/Volume Stats
| Current price | $1.01 | 52-week high | $4.02 |
| Prev. close | $0.95 | 52-week low | $0.91 |
| Day low | $0.93 | Volume | 26,300 |
| Day high | $1.01 | Avg. volume | 103,620 |
| 50-day MA | $1.16 | Dividend yield | N/A |
| 200-day MA | $1.78 | Market Cap | 56.56M |
Medicenna Therapeutics Corp. (MDNA) Company Bio
Medicenna Therapeutics Corp. operates as an immuno-oncology company. The Company develops and commercializes therapeutics for the treatment of central nervous system and urological cancers. Medicenna Therapeutics offers its services in Canada.
Latest MDNA News From Around the Web
Below are the latest news stories about Medicenna Therapeutics Corp that investors may wish to consider to help them evaluate MDNA as an investment opportunity.
MDNA: Encouraging Early Clinical Data from ABILITY Study…David Bautz, PhD NASDAQ:MDNA READ THE FULL MDNA RESEARCH REPORT Business Update Encouraging Early Clinical Data for ABILITY Trial On December 22, 2021, Medicenna Therapeutics Corp. (NASDAQ:MDNA) announced encouraging early clinical data from the Phase 1/2 ABILITY Study (A Beta-only IL-2 ImmunoTherapY Study) of MDNA11 in patients with advanced solid tumors. Following the first two dose escalation |
Medicenna to Participate in the 11th Annual SVB Leerink Global Healthcare ConferenceTORONTO and HOUSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Dr. Fahar Merchant, President, CEO and Chairman of the Board of Medicenna, will participate in a Fireside Chat at the SVB Leerink Global Healthcare Conference, which is scheduled to take place virtually from February 14 – February 18, 2022. Details are as follows: 11th Annual SVB Leerink Global |
Medicenna Reports Third Quarter Fiscal 2022 Financial Results and Operational Highlights-- Phase 1/2 ABILITY study of MDNA11 on track with first set of efficacy results from early dose escalation cohorts expected in mid-calendar 2022 -- Preliminary pharmacodynamic data show preferential stimulation of anti-cancer immune cells with MDNA11 treatment in the ABILITY study -- First clinical site in the US open for enrolment -- Management hosting conference call and webcast today at 8:30 am ET TORONTO and HOUSTON, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna |
Medicenna to Announce Third Quarter Fiscal 2022 Financial Results and Operational Highlights on Wednesday, February 9, 2022TORONTO and HOUSTON, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that it will host a conference call and live webcast on February 9, 2022 at 8:30 AM ET to report its third quarter fiscal 2022 financial results and operational highlights. To access the call, please dial (877) 407-9716 from the Canada and the United States or (201) 493-6779 internationally, followed |
Medicenna Announces Formation of its Scientific Advisory BoardTORONTO and HOUSTON, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced the formation of its Scientific Advisory Board (SAB) comprised of thought leaders in cancer immunotherapy, immuno-engineering and immune monitoring. Chaired by Sergio Quezada, Ph.D., the SAB will work cohesively with management to explore the full potential of Medicenna’s Superkine platform. “I’m del |
MDNA Price Returns
| 1-mo | -8.18% |
| 3-mo | -32.67% |
| 6-mo | -46.28% |
| 1-year | -74.04% |
| 3-year | 59.06% |
| 5-year | N/A |
| YTD | -38.04% |
| 2021 | -65.17% |
| 2020 | 80.00% |
| 2019 | 401.74% |
| 2018 | -67.63% |
| 2017 | N/A |
Loading social stream, please wait...